Blog

PhoreMost, NeoPhore secure Innovate UK funding for small-molecule cancer immunotherapy program – Pharmaceutical Business Review

PhoreMost, NeoPhore secure Innovate UK funding for small-molecule cancer immunotherapy program
Pharmaceutical Business Review
The companies are partners on a grant titled, "A novel small molecule approach to enhance cancer immunotherapy." Their research plan proposes to develop small-molecule drugs that will stimulate cancer immunity by leveraging well-validated genetic

and more »

2018-04-30 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.